Global pharmaceutical and biotechnology company Wockhardt has received the bulk active pharmaceutical ingredient (API) for producing the Oxford-Astrazeneca vaccine at their UK plant and the company will be manufacturing fully finished vaccines for the UK government.
Speaking in an interview to CNBC-TV18, Habil F Khorakiwala, Founder, Chairman & Group CEO of the company said his company will be producing 160 million doses in a year with a revenue potential of USD 100 million.
“We believe emerging markets likely to have more challenges in terms of availability of vaccine. We are in discussion with a number of manufacturers who are near approval or at a fairly advanced progress in their clinical trials and we are offering them our contract manufacturing organization (CMO) facility for making bulk vaccine in India,” he said.
Speaking about vaccine revenue, Khorakiwala said, “Some revenue may come in this quarter but mostly it will come in Q4 of FY21.”
For entire interview, watch video